MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Ocular Therapeutix, Inc. (NASDAQ: OCUL),* Inc, formerly I-Therapeutix*
Organization & Developments: Ocular Therapeutix
Parents
Ocular Therapeutix, Inc. (NASDAQ: OCUL),* Inc, formerly I-Therapeutix*
Children
*Biopharmaceutical company focused on retinal diseases, leveraging its sustained-release hydrogel platform to reduce treatment burden in chronic eye conditions.
*Ocular is advancing hydrogel technology for protecting the eye after ophthalmic surgeries and for delivering drugs to the eye.
*Ocular Therapeutix, Inc. is a privately held company focused on the development and commercialization of ophthalmic therapeutic
*ReSure is the 1st and only sealant with FDA approval for ophthalmic use, providing an alternative to surgical sutures.
2014: Ocular Therapeutix lands FDA approval for ReSure sealant
2016:2 Must-Have Small Biotechs For The Third Quarter- Array and Ocular Therapeutix (NASDAQ:OCUL).
2017: Ocular Therapeutix Hit by Subpoena, SEC Seeks Eye Pain Drug Documents_xconomy
2019: Ocular Therapeutics: Breaking News_seekingalpha.com
2020: Ocular Therapeutix: This Platform Technology Story Continues To Impress
2021: Ocular Therapeutix: Catalysts Stacking
2021: Ocular Therapeutix: Good Medicine, High Competition
2022: Ocular Therapeutix: Good Potential, But Not That Good An Execution_ seekingalpha.com
2024: Ocular Is Now Thoroughly Derisked_seekingalpha.com
2024: Ocular Therapeutics' Impressive Surge: A Strategic Insight
2024: Ocular Therapeutix lays off 13% of workforce
2024: Ocular Therapeutix shifts to retina-focused treatments
2024: Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD_ seekingalpha.com
2024: Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
2024: Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
2024: Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors_ seekingalpha.com
2024: Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
2025: Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade)
2025:Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Jumps
*Key People: Ocular Therapeutix
Finance & Acquisitions: Ocular Therapeutix